Pharmaceuticals
HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
* Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity * Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational...
2026-10-22 18:00
2044
Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission
SEONGNAM, South Korea, Oct. 22, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)', its RNA...
2026-10-22 13:30
2015
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
* Becomes the 7th International Registrational Clinical Trial for Ivonescimab * Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its ...
2026-10-21 20:42
2287
China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right
TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"),today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termi...
2026-10-21 20:00
3903
Samsung Biologics Reports Third Quarter 2026 Financial Results
* Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion * Plant 5 ramp-up and U.S. manufacturing operations contribute to earnings performance * Raised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion...
2026-10-21 15:00
3447
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value
* 64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care. * More than 10 studies have been selected to highlight the latest findings on HER2- and HER3-targeted anti...
2026-10-21 10:09
1784
AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™
Exclusive co-promotion agreement combines AROA's regenerative tissue technology with Mölnlycke's wound care expertise and commercial reach AUCKLAND, New Zealand, Oct. 20, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, has entered into an exclusive ag...
2026-10-21 08:00
2191
Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment
* Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. * Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone payment from Servier. * The multi-t...
2026-10-20 21:00
3419
New Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVD
A Collaboration Leads to Molecularbiological Innovation MUNICH, Oct. 20, 2026 /PRNewswire/ -- AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAM...
2026-10-20 14:10
1366
Sisram Medical Announces NMPA Acceptance of Profhilo Registration Application for Facial Indication
Advancing Commercialization Preparations to Expand Injectables Presence in China HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today a...
2026-10-20 09:00
2271
WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year
SHANGHAI, Oct. 19, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year. Frost & S...
2026-10-20 08:00
3034
Versiti becomes 10th U.S. blood center to adopt FDA-cleared automation from Terumo Blood and Cell Technologies
Automated whole blood processing will expand platelet production capacity and
help meet growing hospital demand
LAKEWOOD, Colo. and MILWAUKEE, Oct. 19, 2026 /PRNewswire/ -- Versiti has
become the 10th U.S. blood center to adopt the Reveos™ Automated Blood
Processing System
2026-10-19 22:00
4527
Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026
Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University Presentation brings previously announced clinical findings together with pharmacokinetic and biomarker evidence for scientific discussion Ba...
2026-10-19 21:00
2726
Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer
SUZHOU, China and PRINCETON, N.J., Oct. 19, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved the appointment of Ms. Jennie Ma as Chief Financial Officer (CFO) of the Company. In this role, Ms. Ma will oversee the Company's financi...
2026-10-19 20:00
2004
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit TherapeuticsInc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194). Built on Akeso's first-in-class immuno-oncology (IO) c...
2026-10-19 19:59
2145
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data onits Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv") in locally...
2026-10-19 10:00
3908
Tsingke Customer Quality Audit Highlights Manufacturing Systems and Quality Controls
BEIJING, Oct. 14, 2026 /PRNewswire/ -- As synthetic biology expands into new applications, standardized manufacturing processes, reliable production data, and robust quality management systems are becoming increasingly important. Tsingke recently hosted an on-site customer quality audit conducted...
2026-10-14 22:19
1601
Lunit SCOPE Reveals HER2 Expression Differences Linked to Treatment Response Beyond Conventional Testing in Nature Medicine Study
AI-powered whole-slide analysis provides insights into treatment response beyond conventional HER2 classification SEOUL, South Korea, Oct. 14, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced findings from a study p...
2026-10-14 21:00
2408
Neurophet Honored with Two Awards at the BioSpectrum Asia Excellence Awards 2026
* Receives Awards for MedTech Innovation and AI-Driven Clinical Development; Only Korean Company Recognized in Two Categories * Recognized for its capabilities in AI-driven clinical support and ICL services, with plans to expand partnerships with global CROs SEOUL, South Korea, Oct. 14, 2026 /...
2026-10-14 21:00
2104
AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases
* Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, setting a new record for the company's annual pipeline output efficiency. * AI-Enabled Molecular ...
2026-10-13 21:00
3875
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 296 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Taishin International Bank Opens Flagship Private Banking Branch in Southern Taiwan
[Picked up by 270 media titles]
2026-10-23 19:08
Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
34957
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
33357
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
32122
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
27281
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
2026-10-21 15:00
15342